This phase III trial studies computed tomography (CT) to see how well it works compared to conventional assessments of tumor response in evaluating tumor response in patients with kidney cancer that has spread to other parts of the body who are receiving targeted therapies. Comparing results of CT scans done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.
Additional locations may be listed on ClinicalTrials.gov for NCT01224288.
See trial information on ClinicalTrials.gov for a list of participating sites.
PRIMARY OBJECTIVES:
I. To determine the change in perfusion parameters derived from dynamic contrast enhanced computed tomography (DCE-CT), in patients with metastatic renal cell carcinoma, undergoing three different targeted therapies, eight weeks after initiation of therapy.
SECONDARY OBJECTIVES:
I. To compare, where available, changes in perfusion parameters assessed at first re-staging (approximately 8 weeks) and shortly after initiating therapy (2-7 days), for the three different therapies.
II. To compare changes in perfusion parameters with clinical outcome.
OUTLINE:
Patients undergo dynamic contrast-enhanced computed tomography scan at baseline, at 2-7 days, and at 8 weeks.
Lead OrganizationM D Anderson Cancer Center
Principal InvestigatorChaan S. Ng
